Authors : Vengamamba Tummala, Chilamakuri Kalyani, Saikrupa Vadlapudi, Nagalaxmi Jangiti, Beri Abhilash Sai, Kotha Balasubramanyam
DOI : 10.18231/j.ijca.2021.097
Volume : 8
Issue : 4
Year : 2021
Page No : 5-9
Introduction: Coronavirus disease 2019 (COVID-19) is a contagious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Remdesivir, a broad spectrum antiviral agent, is currently the only drug that is approved by the Food and Drug Administration for the treatment of COVID-19. It is recommended for use in hospitalized patients who require supplemental oxygen. There are insufficient data either for or against to recommend for routine use of Remdesivir in high risk patients who doesn’t require supplemental oxygen.
Aim: To evaluate the efficacy of Remdesivir in covid positive patients.
Materials and Methods: A retrospective analysis of 300 patients was done, out of which 150 patients belong to Group 1 and 150 patients belong to Group 2. Group 1-Elderly patients with comorbidities who doesn’t require supplemental oxygen Group 2- Patients requiring oxygen supplementation (SpO2 88% to 94% on room air).
Results: Group 1 patients were discharged earlier than Group 2 patients.
Conclusion: Elective use of Remdesivir has a definitive role in prevention of progression of disease especially in high risk susceptible individuals.
Keywords: Remdesivir, COVID 19, Elderly patients, Hypoxia, Oxygen supplementation.